MedicaidPrior AuthMedium impact
Asparlas™ (calaspargase pegol-mknl) (New)
Humana·OH · Oncology, Hematology, Pediatrics·Medicaid
Effective date
Dec 1, 2025
We identified it
Jun 24, 2026
Summary
Humana Medicaid Ohio has established a new prior authorization policy for Asparlas™ (calaspargase pegol-mknl), a chemotherapy drug for treating acute lymphoblastic leukemia in patients ≤21 years old. Prior authorization is required starting December 1, 2025, with specific clinical criteria including diagnosis of ALL, use as part of multi-agent chemotherapy, and age restrictions.
Action Required
By December 1, 2025: Billing team must update prior authorization requirements for Asparlas™ (calaspargase pegol-mknl) prescriptions for Humana Medicaid Ohio patients. Providers must verify patient meets all criteria (ALL diagnosis, age ≤21 years, multi-agent chemotherapy regimen) and obtain prior authorization before prescribing. Update billing system to flag this medication for prior auth review. Failure to obtain prior authorization may result in claim denials.